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Abstract: Protein microarrays are useful tools for highly multiplexed determination of 
presence or levels of clinically relevant biomarkers in human tissues and biofluids. 
However, such tools have thus far been restricted to laboratory environments. Here, we 
present a novel 384-plexed easy to use lateral flow protein microarray device capable of 
sensitive (<30 ng/mL) determination of antigen-specific antibodies in ten minutes of total 
assay time. Results were developed with gold nanobeads and could be recorded by a   
cell-phone camera or table top scanner. Excellent accuracy with an area under curve (AUC 
of 98% was achieved in comparison with an established glass microarray assay for 26 
antigen-specific antibodies. We propose that the presented framework could find use   
in convenient and cost-efficient quality control of antibody production, as well as in 
providing a platform for multiplexed affinity-based assays in low-resource or   
mobile settings. 
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1. Introduction 
Protein microarrays are widely used tools for diagnostic biomarker analysis, with proven utility in 
such varied fields of human medicine as for instance autoimmunity, allergy, infection and cancer [1]. 
In particular, the ability of protein microarrays to simultaneously determine presence or levels of a 
large number of biomolecules is useful as a means to screen a clinical sample for a variety of different 
conditions such as cancers or autoimmune diseases that have not yet started to manifest as symptoms 
or other detectable signs of disease [2], or it can serve to refine the resolution in the differentiation 
between for instance infections from closely related bacterial hosts [3]. Further, protein microarrays 
may improve the diagnostic accuracy in cancer diagnosis [4]. As all the individual microspot assays 
simultaneously taking place on a microarray are directed to the exact same sample, the potential variability 
arising from aliquot preparations for the same number of simplex-assays is also conveniently avoided.  
The assay procedures for protein microarrays are low- to moderately labor-intensive, and may due 
to the ambient-analyte conditions governing the microspot assay dynamics offer excellent sensitivity 
on par with ELISAs [1]. However, due to the many assay steps involved and the required convective 
mixing in the sample incubation step, microarray assays are typically carried out manually, requiring 
skilled personnel and well-equipped laboratories. Further, as fluorescent probes remain the preferred 
choice for detection due to excellent sensitivity and high dynamic range, expensive and bulky   
laser-equipped high-end scanners are usually needed.  
Manual handling and advanced detection strategies result in assay times normally spanning several 
hours and consequently current microarray technologies are not well suited for mobile, on-site or point 
of care applications. While it is likely that a large proportion of microarray analyses could preferentially 
continue to be performed within advanced health care sites such as hospitals or centralized 
laboratories, portable microarray solutions may support more rapid clinical decision making in 
emergency situations in the field or in such areas where little healthcare infrastructure exists. Further, 
point of care microarray tests might serve to relieve health care resources when patients or care-givers 
are able to conduct regular testing themselves. Finally, such portable tests could facilitate those unable 
to go to a hospital or health care point for testing [5].  
While there is a wide variety of simple portable tests commercially available, including for instance 
rapid tests for sexually transmitted diseases, cardiovascular disease and allergies, such tests are 
typically simplex or low-plex, with limited quantitative ability and sensitivity, and may further suffer in 
diagnostic accuracy [6]. Thus, considering the great advances made in diagnostic protein microarrays, 
we believe that there exists a major potential health care benefit if microarray technologies could be 
made amenable for portable, rapid point-of-care use. 
A considerable hurdle for creating portable, easy to use planar microarray solutions appears to be 
the accommodation of many sequential assay steps on-chip, as well as the need for comprehensive 
sample mixing in order to avoid long assay times due to large diffusion coefficients of protein 
biomarkers. These challenges are largely avoided in immunochromatographic/lateral flow-based tests, Int. J. Mol. Sci. 2011, 12  7750 
 
 
and to this end we previously demonstrated the feasibility of combining a lateral flow/dipstick assay 
framework commonly used in simplex/low-plex rapid tests with protein microarray patterning for 
rapid and accurate determination of levels of bovine IgG raised towards mycoplasma infection [7] 
using a cell phone digital camera or consumer table top scanner for array imaging.  
In this paper, we expand the concept into a general high-plexed lateral flow protein microarray 
(LFM) strategy, with 384 protein fragments (approximately 80–100 aa) [8] immobilized in a 24 × 16 
microarray pattern on nitrocellulose. The protein fragments are a subset of antigens used for the   
large-scale generation of monospecific antibodies within the Human Protein Atlas (HPA) [9] where the 
aim is to by 2015 generate a set of highly specific antibody binders for the complete human proteome. 
In the HPA, bioinformatically designed protein fragments are employed as immunogens, as well as 
ligands in the subsequent affinity purification and quality control/validation of the generated antibody 
reagents. Together with the obvious benefit of providing reagents for determining presence or levels of 
virtually any expressed human protein in tissues or body fluids, there is ongoing work exploring the 
potential of using the protein immunogens as affinity binders for detection of disease-specific antibody 
populations [10]. Thus, investigating alternative microarray assay formats employing protein immunogens 
as affinity binders could result in improved strategies for quality control of raised antibodies as well as 
in novel methods for diagnostic antigen microarray tests.  
In this work, by employing a prototype lateral flow protein microarray device, we were able to 
accurately determine levels of 26 individual HPA antibodies, as well as up to 8 concurrent specific IgG 
analytes in approximately 10 min total assay time. We argue that: (a) the demonstrated concordance 
with an established glass/fluorescence microarray assay; (b) the simplicity of the assay procedure 
drawing from the benefits of common lateral flow/dipstick tests; (c) the highly multiplexed capacity of 
the assay; (d) the short assay time; and (e) the convenient read-out options, make the presented assay 
framework an interesting tool for rapid quality control of raised antibody reagents, and may further 
find use in translating the capabilities of protein microarrays to point of care/low resource settings. 
2. Results and Discussion 
In this study, a novel protein antigen lateral flow microarray containing 384 different capture 
microspots patterned onto a nitrocellulose substrate and with a gold nanobead detection strategy 
(Figure 1) was evaluated in terms of absolute sensitivity and accuracy in comparison with a 
conventional glass/fluorescence-based microarray analysis of 26 IgG antibody species. We also 
investigated the method’s inherent variability as well as its ability to detect mixtures of up to eight 
different specific rabbit IgGs. 
  Int. J. Mol. Sci. 2011, 12  7751 
 
 
Figure 1. (A) Three cardboard-backed nitrocellulose strips attached to a glass array slide. 
Two arrays were printed per strip, but only the data from the upstream array was used in 
this study; (B) Here, an anti-HisABP antibody was used to reveal the pattern of the printed 
antigens which all had been recombinantly fused with a His6ABP-tag. 
 
2.1. Analysis of 26 Specific Rabbit IgG and Assay Accuracy 
A selection of 26 purified rabbit IgG isolates, diluted to 0.17–6.91 µg/mL was analyzed in 
triplicates on the lateral flow microarray as well as on the reference glass slide microarray (Table 1). It 
was found that both platforms could correctly identify all 26 antibodies individually, with signal to 
noise values of 12–181 (mean 100) for the LFM and 23–347 (mean 192) for the glass array. For five 
samples, an additional strong common signal was found by both platforms. Further, on five occasions 
the glass array detected an additional strong signal which was not found by the LFM, whereas the 
LFM only once picked up an additional signal which was not found by the glass array. This may 
suggest that the glass array is more sensitive to weaker interactions, which may or may not be 
beneficial depending on the application. While higher signal to noise values were recorded from the 
glass array, the assay procedure was easier to perform for the lateral flow array, and the difference in 
assay time was substantial, around 10 min for the lateral flow array compared to more than two hours 
for the glass array assay. Further, the distinct red color arising on the lateral flow array allowed 
convenient options of employing a table top scanner or cell-phone camera for the array imaging. We 
propose that the excellent concordance suggests that the sensitivity, accuracy and multiplexing ability of 
glass-based protein microarrays can be retained in the translation into immunochromatographic/lateral 
flow assay frameworks. Int. J. Mol. Sci. 2011, 12  7752 
 
 
Table 1. 26 Antibodies were analyzed with the lateral flow and glass microarray. For all 
antibodies, both methods correctly detected the IgG analyte with the expected antigen spot, 
although the signal to noise was usually greater for glass than LFM. In five cases, one 
additional antigen spot gave rise to a significant signal on both platforms (LG). Five times, 
the glass array gave rise to an additional antigen signal while no signal was seen on the 
LFM (G), whereas the reverse case only occurred once (L). 
Antibody 
sample 
Original 
concentration 
[μg/mL] 
(S/N) 
LFM 
(S/N) 
Glass 
Additional 
signals 
Comment 
HPA Ab1  17  79  251  LG   
HPA Ab2  66  12  51     
HPA Ab3  80  18  85     
HPA Ab4  108  45  145     
HPA Ab5  113  110  221  LG   
HPA Ab6  116  59  156     
HPA Ab7  144  88  253  LG,G   
HPA Ab8  148  173  326     
HPA Ab9  340  123  325  G   
HPA Ab10  141  153  70     
HPA Ab11  104  181  142    High BG glass array 
HPA Ab12  97  84  198     
HPA Ab13  94  94  128    High BG glass array 
HPA Ab14  88  134  156  G   
HPA Ab15  85  125  128     
HPA Ab16  58  48  190    High BG glass array 
HPA Ab17  100  17  23   
Low signals on both 
platforms 
HPA Ab18  93  143  278  G   
HPA Ab19  76  73  164    High BG glass array 
HPA Ab20  50  120  177  G  High BG glass array 
HPA Ab21  48  99  199  LG  High BG glass array 
HPA Ab22  278  179  249  L   
HPA Ab23  164  95  277     
HPA Ab24  183  85  186     
HPA Ab25  188  131  261  LG   
HPA Ab26  691  130  347    High BG glass array 
LG  Additional antigen spot positive for both methods 
G  Additional antigen spot positive for only glass array 
L  Additional antigen spot positive for only lateral flow array 
A good agreement between the lateral flow array and the glass array results was found (Figure 2) and 
the Pearson correlation coefficient was estimated to 0.74. Further, a receiver-operator-characteristics 
analysis was performed to reveal the concordance in terms of sensitivity and specificity for the 
comparison between the methods. While both the lateral flow and the glass array assays required 
thresholds of around 22 to accurately separate positive signals from negative, it was found that the area Int. J. Mol. Sci. 2011, 12  7753 
 
 
under the curve (AUC) could be estimated to 98%, indicating that the antigen microarray could be 
transferred from the conventional glass assay into the immunochromatographic/lateral flow platform 
with retained accuracy.  
Figure 2. (A) Lateral flow and glass microarray results from the analysis of 26 antibody 
samples are compared. Green dots (in the top right quadrant) indicate concordant positive 
signals, black (bottom left quadrant) are concordant negative signals and blue dots (top left 
and bottom right quadrants) represent positive signals that only arose on one platform. All 
expected antibodies were detected by the correct antigen spot on both platforms. The 
Pearson correlation coefficient for the dataset was 0.74. Only signals higher than the mean 
for each array are shown; (B) A receiver-operator-characteristics analysis was performed, 
employing the vertical threshold for the glass array signals indicated in (A). The area under 
the curve (AUC) was found to be 98%, suggesting a very good binary classification 
concordance between the methods.  
 
A moderate correlation coefficient is to be expected due to differences in substrate coupling to the 
protein antigens, as well as substantial differences in assay dynamics. However, the sensitive and 
specific binding of the sample antibodies on the corresponding antigen microspots should be retained, 
and this is indeed what the ROC analysis demonstrates.  
2.2. Assay Sensitivity 
Two antibodies (HPA Ab 9 and HPA Ab 22, due to suitably high initial concentrations) were 
selected for a sensitivity analysis. Each antibody was diluted 1:100, 1:1000, 1:10.000, 1:100.000 in 
assay buffer, and three replicates per antibody were run for each dilution. As compared with the 
negative control, it was found that the sensitivity could be estimated to around 30 ng/mL or better and 
that the response tended to be log-linear (Figure 3).  
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Figure 3. Dilution series of two antibodies, HPA Ab 9 and HPA Ab 22. The antibodies 
were diluted 1:100, 1:1000, 1:10.000 and 1:100.000 and the signal from the expected 
positive antigen spot was measured. It was found that a linear relation between the 
intensity and the log of the concentration was found between dilutions 1:100 and 1:10.000. 
As no significant signals were found at dilutions 1:100.000, it is suggested that the 
sensitivity may reside at or lower than around 30 ng/mL for the lateral flow analysis of the 
two antibodies. 
 
2.3. Assay Variability Investigation 
From the triplicate runs of the total cohort of 26 specific IgG species included in this study (and 
under the assumption that the uncontrolled variation was Gaussian distributed), we calculated the 
standard deviation of each analyzed antibody. We found that the average coefficient of variation 
(%CV) was 13% [5%–21%]. The level of variability may impede highly resolved quantitative analysis, 
but could still be acceptable for semi-quantitative approaches. 
2.4. Analysis of IgG Mixed Samples 
In order to demonstrate the array’s capability of detecting an increasing number of antibody 
analytes, we created mixtures of 2, 2, 4 and 8 antibodies to be analyzed on the lateral flow microarray. 
It was found that the array could accurately identify all the constituents of the mixes, although the 
positive signal to noise ratios gradually decreased (Figure 4) due to increasing background/array mean 
intensities. The increased array mean was expected, and did conceivably arise due to the increased 
concentration of total IgG in the mixed samples, which amounted to around 15 µg/mL in total for the 
8-mix, in comparison to between 0.17 and 6.9 for the individual antibodies (in the case of the antibody 
HPA Ab 26 which was analyzed at 6.9 µg/mL, the background was already substantial). Thus, it 
appears likely that at least 8 different antibody species may be detected simultaneously by the lateral 
flow microarray, given that the sample dilution keeps the total IgG concentration at or below a critical 
level (15 µg/mL in this study). 
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Figure 4. Four antibody mixes were prepared, two containing two antibodies, one 
containing four antibodies, and one containing eight antibodies. In all cases, the 
signal/noise on the expected antigen (Ag) spots were distinctly higher than the highest 
unexpected antigen signal on the same array, although the S/N decreased with increased 
number of antibodies in the mix.  
 
3. Experimental Section 
3.1. Protein Antigens and Antibodies 
All protein antigens were selected from the antibody quality control division of the HPA project [11]. 
The antigens are 80 to 100 amino acid long protein epitope signature tags that are computationally 
chosen from the protein encoding genetic sequence and fused with a His6-albumin binding protein 
domain [8]. Antigens are designed to exhibit low signal similarity to other human proteins and encode 
for no transmembrane regions. Following design, the antigens are recombinantly expressed in E. coli 
and the protein product subsequently affinity purified under denaturing conditions before being 
immunized into rabbits to stimulate antibody production. The antibodies are harvested from the rabbit  
after 4 months and purified by means of affinity chromatography using the immunogens/antigens as   
affinity ligands [12]. 
3.2. Buffers 
Protein antigens were diluted in printing buffer (50 mM sodium carbonate-bicarbonate buffer + 
49% glycerol, pH 7.4) before patterning on substrates. The assay buffer used for most dilutions and 
washes contained phosphate buffered saline (PBS) + 0.5% Tween20, together with 3% bovine serum 
albumin (Sigma) and 1% sucrose (Sigma) at pH 7.4.  
3.3. Lateral Flow Microarray Substrate and Patterning 
Cardboard-backed nitrocellulose membranes (HighFlowPlus90, Millipore) were cut into 12 by   
25 mm strips and glued to 0.8 mm thick arraying slides (Arrayit) with off-the-shelf super glue (Loctite 
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Super Glue Precision, Henkel). 384 individual protein antigen capture probes were then spotted onto 
the membranes using an Arrayjet Marathon (Arrayjet Ltd.) at 80 µg/mL in printing buffer. The array 
blocks were printed in a 16 by 24 spot layout with 280 µm distance between spot centers (Figure 1). 
Approximately 100 pL sample was deposited on each spot. The printed arrays could be stored dry at 
room temperature for up three months without apparent loss of sensitivity (data not shown). 
3.4. Glass Microarray Patterning and Assay Procedure and Detection 
The patterning of glass microarrays was carried out using the same printing protocol as for the 
lateral flow microarray, but using epoxy-derivatized glass slides (OPEpoxy slides, Captital Bio) as 
substrates. After printing, slides were allowed to rest at 37 °C for 24 h, after which slides were blocked 
in PBS + 0.1% Tween20 + 3% BSA for 1 h on a shaker at 160 rpm. Slides were then washed three 
times with PBS for 5 min each, followed by brief rinsing in deionized water and finally drying by 
spinning 2 × 3 min at 700 rpm. The assay procedure for the use of glass slide antigen arrays in the 
analysis and quality control of rabbit sera has been described elsewhere [12]. Briefly, slides were 
incubated with the antibody sample for 60 min on a shaker table at 150 rpm. An adhesive silicone 
mask (Schleicher and Schuell) was clamped on the slide in order to separate the 16 array blocks. 
Subsequently, the arrays were washed twice for 5 min on a shaker at 110 rpm with PBS + 0.1% 
Tween. Next, the arrays were incubated with a fluorescent secondary antibody (Goat anti-rabbit Alexa 
647, Invitrogen) for 1 h at 4 ng/mL, followed by washing of the arrays for 5 min on a shake at  
110 rpm with PBS + 0.1% Tween20. After the slide had been dried by means of spinning, it was 
scanned using an array scanner G25O5B (Agilent Technologies) and analyzed by means of the 
software GenePix Pro 5.1 (Axon Laboratories). 
3.5. Lateral Flow Microarray Assay Procedure 
A 1 mm thick line of grease (Spezialfett #3500, Heraeus) was applied 2 mm from the top end of 
each strip across the width of the membrane, forming the lower boundary of a sample drop-in area. 
The resulting hydrophobic barrier forced the sample to travel only through and not on top of the 
nitrocellulose membrane. A cotton sheet (Whatman) of around 1 × 2 cm was placed at the end of the 
membrane to serve as a fluid sink. Initially, the membrane was presoaked with 30 µL assay buffer in 
order to avoid non-specific binding and provide a homogeneous flow profile. Subsequently, 30 µL 
antibody sample was applied, followed by a 15 µL wash with assay buffer. Next, 30 µL of   
biotin-conjugated goat anti-rabbit F(ab’)2 (Jackson Immunoresearch) was applied, again followed by a 
15 µL wash step. Finally, 30 µL of OD10 40 nm monoclonal goat anti-biotin coated gold particles 
(British Biocell International) diluted 1:3 in assay buffer was applied, followed by a 30 µL wash step. 
Each applied liquid step needed around 90 seconds to complete, giving a total assay time of around  
10 minutes. As a quality control step to ensure all antigen spots had been printed satisfactorily, a  
100 µg/mL rabbit anti-HisABP antibody (generated in house from HPA project) was applied to one 
strip instead of rabbit IgG solution, which resulted in binding to the His6ABP-tag present on all 
antigens (Figure 1). In all assays, each consecutive step was initiated immediately after the depletion of 
the previous step’s entire droplet into the drop-in area. 
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3.6. Image Acquisition and Data Analysis 
After drying (1–5 min depending on the surrounding temperature and humidity), the arrays were 
scanned using a standard tabletop HP Scanjet 8270 (Hewlett Packard) at 1200 dpi. 16 bit gray scale tiff 
images were acquired by VueScan 8.6.34 (Hamrick Software) and subsequently inverted and analyzed 
using GenePix Pro 5.1 (Axon Instruments). Data analysis was performed with the statistical language 
R version 2.12 [13]. The median spot intensity subtracted by the inter-spot background was used for 
both lateral flow and glass microarray data. Signal to noise values were calculated by dividing   
each array microspot intensity with the array mean of background-subtracted spot intensities. For   
receiver-operator-characteristics analysis, a glass array threshold was selected that most accurately 
separated the expected (from the immunization pattern) positive signals from the expected negative 
ones, creating a binary vector of all antibody samples in the cohort. Subsequently, the corresponding 
array of sample data resulting from the lateral flow array analysis was compared to the binary vector 
employing the ROCR package in R. 
4. Conclusions 
Efforts to discover novel clinically useful biomarkers is continuously generating better molecular 
tools that through earlier and more accurate diagnosis and better disease monitoring may eventually 
greatly reduce the global burden of disease [14]. A key challenge lies in translating the wealth of 
improved diagnostic potential from research into clinical practice. While current microarray 
technologies are well suited to handle a high number of novel affinity binders, point of care tests are 
lagging behind in terms of multiplexing ability, sensitivity and diagnostic accuracy. Here, we present a 
novel device which draws its speed, portability and ease of use from the widely used lateral flow rapid 
test and the sensitivity, accuracy and multiplexing ability from the planar microarray. The sensitivity 
was found to be at or better than around 30 ng/mL, a level which should be acceptable in many  
IgG-based assays where disease-specific IgG are typically in the order of µg/mL or higher. The 
average variability was estimated to 13% CV which could be suitable at least for semi-quantitative 
analyses. Further, in comparison with a conventional glass/fluorescence microarray assay, we show 
that the concordance between the methods for a set of 26 rabbit IgG antibodies was excellent, with an 
AUC of 98%, suggesting that the lateral flow microarray could prove useful as an alternative in quality 
control for high-throughput antibody generation as well as for future potential rapid and portable 
diagnostic protein antigen microarrays. A brief qualitative comparison between the lateral flow array 
and glass array assay systems with regards to some relevant performance parameters can be found in 
table 2. We believe an important novel finding is that the nitrocellulose substrate, which has proven 
immensely useful for rapid and simple immunochromatography tests, appears amenable for high-
density protein microarray analysis with retained diagnostic accuracy. Coupled to a detection strategy 
involving gold nanobeads, the LFM allowed for a flexible and convenient detection and read-out 
strategy along with the powerful analytic ability of the microarray. In future work we will select a 
similarly sized set of protein antigens which have demonstrated a clinically relevant diagnostic utility 
and evaluate the lateral flow microarray’s ability on clinical samples. We will also attempt to develop Int. J. Mol. Sci. 2011, 12  7758 
 
 
the device further for less manual operation and towards integration of filtration steps for whole-blood 
analysis and automated image analysis. 
Table 2. Qualitative comparison of some aspects of the lateral flow and glass array   
assay formats.  
Glass array  Lateral flow array 
Multiplexing ability  High  High 
Sensitivity High  Medium 
Reproducibility Medium  Medium 
Cost/assay Medium/High  Low 
Assay time  ~2 h  ~10 minutes 
Procedure difficulty  Medium  Low 
POC potential  Low  High 
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